Laurus Labs Ltd
Laurus Labs Q2 FY26 earnings call: Revenue & Margins
Q2 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
Animal Health segment: Expected to contribute meaningfully and continue growing over the next financial year and beyond (Page 17). Laurus Labs expects continued strong growth driven by ARV business, sustained CDMO momentum, and generic business expansion.
From Laurus Labs Ltd's Q2 FY26 earnings-call transcript · updated 16 Oct 2026.
Revenue & Sales Performance
- Animal Health segment: Expected to contribute meaningfully and continue growing over the next financial year and beyond (Page 17).
- CDMO business: Anticipated overall growth over the year with healthy demand momentum; commercial late-stage supplies will persist, though clinical supplies may also vary (Page 17).
- ARV business: Slight increase in overall demand from existing customers with higher shipment volumes this year (Page 11).
- Generic division: Reported 20-28% growth in recent quarters; benefits from new product launches and stabilized product lines expected to continue (Page 5).
2 more points from Laurus Labs Ltd's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Laurus Labs Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Laurus Labs plans about INR 250 crores of capex and opex investment over the next 3 years for genes and ADC facilities, expected to be completed by CY 2026.
- A significant greenfield capex of around INR 1,000 crores per year is planned, mainly focused on new modalities and fermentation capacities.
- The company has acquired a new 530-acre land complex with a planned investment of US$600 million (around INR 4,800 crores) over 8 years, separate from capex on the existing land bank.
- Total capex over the 8-year horizon, including existing and new land, could approach INR 8,000 crores.
- Capex will be funded by internal accruals and debt; no equity dilution is planned.
2 more points from Laurus Labs Ltd's call on capex
Pro opens every point from 15K+ earnings calls
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Laurus Labs Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Multiple product validations are ongoing in the Animal Health segment, with one already commercially supplied and others in validation phases (Page 17).
- Significant revenue is expected after validation completion and commercial supply commencement (Page 17).
- CDMO segment shows strong order flow with a good mix of big pharma and biotech clients; late-phase clinical programs are increasing (Page 4).
- Robust pipeline momentum and RFP flow continue, driven by complex chemistries and advanced modalities (Page 4).
- Increased customer interest for dedicated fermentation lines supports ongoing capacity expansions (Page 4).
2 more points from Laurus Labs Ltd's call on order book
Pro opens every point from 15K+ earnings calls
Laurus Labs Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹1.8K Cr, net profit ₹282 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Laurus Labs Ltd's management said in earlier quarters
- Q1 FY27 earnings call analysis →
- Q3 FY25 earnings call analysis →
- Q4 FY25 earnings call analysis →
- Q3 FY26 earnings call analysis →
- Q1 FY26 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
- Q2 FY24 earnings call →
- Q1 FY24 earnings call →
Others in Pharmaceuticals & Biotechnology this season
- Bajaj Healthcare (Q2 FY26)
For HYE (Half Year Ending) Sept 2025, Total Income reported is ₹299.28 crore. Key investor presentation takeaways from Bajaj Healthcare Ltd's Q2 FY26 investor p
- Infinium Pharma (Q2 FY26)
Revenue from Operations for H1FY26: Rs 84.05 crore, a 1% YoY increase from Rs 82.98 crore in H1FY25 (Page 22). Key investor presentation takeaways from Infinium
- Wanbury (Q2 FY26)
Q2FY26 Revenue from Operations: ₹160.06 Crore . Key investor presentation takeaways from Wanbury Ltd's Q2 FY26 investor presentation — and how it ranks against
- Balaxi Pharma (Q2 FY26)
Revenue for Q2 FY26: ₹56.17 crore . Key investor presentation takeaways from Balaxi Pharma's Q2 FY26 investor presentation — and how it ranks against sector pee
Arthneeti Pro · Annual
Laurus Labs Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Laurus Labs Ltd Q2 FY26 results?
Animal Health segment: Expected to contribute meaningfully and continue growing over the next financial year and beyond (Page 17). Laurus Labs expects continued strong growth driven by ARV business, sustained CDMO momentum, and generic business expansion.
What is Laurus Labs Ltd share price analysis?
Laurus Labs Ltd currently shows a neutral. The stock trades at a P/E of 101.8 with a market cap of ₹111,337 Cr. Investors should review the full earnings analysis for detailed insights.
Is Laurus Labs Ltd planning capital expenditure?
Laurus Labs plans about INR 250 crores of capex and opex investment over the next 3 years for genes and ADC facilities, expected to be completed by CY 2026.
Keep Laurus Labs Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.